Clot buster may stop promising stroke medicine from working properly

Clot buster may stop promising stroke medicine from working properly

A clotbusting drug commonly used to treat ischemic stroke interacts negatively with a promising anti-inflammatory treatment (anakinra), underscoring the need to test new stroke therapies alongside existing standard care. According to The University of Manchester–led study on mice, published in Stroke, the timing of anakinra must be adjusted to avoid reducing the benefits of the clot-busting therapy known as tissue plasminogen activator (tPA).

Blood clot drug may harm stroke treatment, study finds

Stroke is one of the most serious medical emergencies in the world. It happens when blood flow to part of the brain is suddenly blocked or reduced. Without enough blood and oxygen, brain cells begin to die within minutes. This can lead to long-term disability or even death. In fact, stroke is the second leading […] The post Blood clot drug may harm stroke treatment, study finds appeared first on Knowridge Science Report.